News from veloxis pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 31, 2019, 17:50 ET Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress

Veloxis Pharmaceuticals (OMX: VELO) announced today that the Company's product, Envarsus XR (tacrolimus extended-release tablets), will be the...


May 06, 2019, 12:41 ET Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2019

Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the first three months of 2019. This Company Release should be read in ...


Jan 02, 2019, 19:40 ET Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Mark Hensley to Chief Commercial Officer. Mr. Hensley has served as the...


Dec 19, 2018, 17:37 ET FDA Approves New Indication for ENVARSUS XR® (tacrolimus extended-release tablets)

Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus...


Nov 14, 2018, 15:37 ET Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights

Highlights Product revenue for first nine months of 2018 was USD 27.8 million, an increase of 101% compared to the same period last year. U.S....


Oct 31, 2018, 15:16 ET Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Ira Duarte to Chief Financial Officer. Ms. Duarte has served as the...


Oct 10, 2018, 18:35 ET Veloxis to Present at the Jefferies 2018 London Healthcare Conference

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that CEO Craig Collard will present at the Jefferies 2018 London Healthcare Conference at...


Aug 13, 2018, 13:53 ET Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018

Highlights Veloxis upgrades 2018 Outlook based on strong performance. Product revenue for first half of 2018 was USD 17.2 million, an increase of...


May 16, 2018, 06:13 ET Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Highlights Product revenue for Q1 2018 was tUSD 7,265 an increase of 142% compared to the same period last year. U.S. revenue increased 150% to tUSD...


Mar 28, 2018, 04:29 ET Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®

Veloxis Pharmaceuticals A/S is pleased to announce the publication of Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of ...


Mar 07, 2018, 06:32 ET Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®

Veloxis Pharmaceuticals A/S announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration...


Feb 27, 2018, 03:03 ET Veloxis Pharmaceuticals Releases Annual Report for 2017

Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Annual Report for the financial year 2017. A complete copy of Veloxis's Annual Report for ...


Nov 14, 2017, 12:27 ET Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017

Highlights Record product revenue of tUSD 5,924 achieved in Q3 2017. Revenue reached tUSD 22,092 in the first nine months of 2017 representing an...


Sep 13, 2017, 18:23 ET Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Veloxis Pharmaceuticals A/S (OMX: VELO) is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its...


Aug 16, 2017, 13:38 ET Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017

Highlights Revenue reached tUSD 16,168 in the first half of 2017 representing an increase of 394% compared to the same period last year. U.S. revenue ...


Dec 07, 2015, 02:35 ET Veloxis Launches Envarsus®XR for Treatment of Kidney Transplant Patients in U.S.

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of...


Nov 11, 2015, 05:12 ET Veloxis Pharmaceuticals announces financial results for the first nine months of 2015

Highlights: On 30 September, 2015, Veloxis had cash and cash equivalents of DKK 157.6 million, and the Company's cash position is expected to be in...


Aug 26, 2015, 01:21 ET Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook

Highlights: On 14 August, 2015 Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ...


May 20, 2015, 01:33 ET Veloxis Pharmaceuticals announces financial results for the first three months of 2015

Highlights: Veloxis has announced that once-daily Envarsus® XR, an investigational new drug under FDA review for the prevention of organ rejection in ...


Dec 19, 2014, 09:41 ET Veloxis Comments on U.S. District Court Order

Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by the U.S. District Court for the...


Nov 12, 2014, 01:10 ET Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook

Highlights: On 31 October the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus® XR. FDA stated that the...


Aug 20, 2014, 01:42 ET Veloxis Pharmaceuticals announces financial results for the first six months of 2014

Highlights: On 28 July the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney...


May 22, 2014, 02:35 ET Veloxis Receives Positive Opinion from CHMP for Envarsus® for Treatment of Both Kidney and Liver Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...


May 14, 2014, 12:59 ET Veloxis Pharmaceuticals announces financial results for the first three months of 2014

Highlights: The U.S. Food and Drug Administration (FDA) has accepted for standard review the company's New Drug Application (NDA) for Envarsus® for...


Apr 28, 2014, 11:00 ET Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to...